46 patents
Page 2 of 3
Utility
Metabolites of [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 Yl}-phenoxy)-propyl]-diethyl-amine
15 Jul 21
The present invention relates to metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine.
William Kenneth Banner, Bapu Gaddam, Dharma Rao Polisetti, Robert Carl Andrews, Samuel Victory
Filed: 25 Mar 21
Utility
Phenoxy Acetic Acids and Phenyl Propionic Acids As Ppar Delta Agonists
24 Jun 21
Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein.
Per SAUERBERG, Pavel PIHERA, Zdenek POLIVKA, Miroslav HAVRANEK, Ingrid PETTERSSON, John Patrick MOGENSEN
Filed: 9 Mar 21
Utility
Therapeutic Uses of Glucokinase Activators In Combination with Insulin or Insulin Analogs
10 Jun 21
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs.
Jennifer L.R. FREEMAN, Maria Carmen VALCARCE LOPEZ
Filed: 18 Feb 21
Utility
Therapeutic Uses of Glucokinase Activators In Combination with Insulin or Insulin Analogs
10 Jun 21
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs.
Jennifer L.R. FREEMAN, Maria Carmen VALCARCE LOPEZ
Filed: 18 Feb 21
Utility
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
23 Mar 21
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs.
Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez
Filed: 13 Jan 20
Utility
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
16 Mar 21
Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein.
Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Petterson, John Patrick Mogensen
Filed: 8 Nov 19
Utility
Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof
11 Mar 21
The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators.
Otis Clinton Attucks
Filed: 20 Nov 20
Utility
Crystalline Forms of [3-(4- {2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL} -Phenoxy)-propyl]-diethyl-amine
11 Mar 21
The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
Zheqiong Wu
Filed: 14 Sep 20
Utility
Pharmaceutically Acceptable Salts of [3-(4- {2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL} -Phenoxy)-propyl]-diethyl-amine
4 Mar 21
The present invention relates to pharmaceutically acceptable salts of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
Juan Hu
Filed: 24 Sep 20
Utility
Therapeutic Uses of GLP1R Agonists
28 Jan 21
Methods of using glucagon-like peptide 1 receptor (GLP1R) agonists are generally disclosed herein.
Jennifer L.R. Freeman, Maria Carmen Valcarce Lopez
Filed: 13 Oct 20
Utility
Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
26 Jan 21
The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators.
Otis Clinton Attucks
Filed: 25 Sep 19
Utility
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
12 Jan 21
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating non-alcoholic steatohepatitis are provided.
Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 10 Jan 20
Utility
Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
6 Jan 21
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided.
Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 21 Sep 20
Utility
Phenoxy Acetic Acids and Phenyl Propionic Acids As Ppar Delta Agonists
8 Jul 20
Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein.
Per SAUERBERG, Pavel PIHERA, Zdenek POLIVKA, Miroslav HAVRANEK, Ingrid PETTERSON, John Patrick MOGENSEN
Filed: 7 Nov 19
Utility
Therapeutic Uses of Glucokinase Activators In Combination with Insulin or Insulin Analogs
13 May 20
Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs.
Jennifer L.R. FREEMAN, Maria Carmen VALCARCE LOPEZ
Filed: 12 Jan 20
Utility
Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
13 May 20
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating non-alcoholic steatohepatitis are provided.
Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 9 Jan 20
Utility
Glucokinase Activator Compositions for the Treatment of Diabetes
6 May 20
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
Maria Carmen Valcarce Lopez, Tung Fong
Filed: 15 Jan 20
Utility
Glucokinase activator compositions for the treatment of diabetes
16 Mar 20
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
Maria Carmen Valcarce Lopez, Tung Fong
Filed: 17 May 18
Utility
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
24 Feb 20
The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4 including, but not limited to, allergic rhinitis.
Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
Filed: 9 Jul 19
Utility
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
24 Feb 20
Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating conditions or diseases of the eye are provided.
Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
Filed: 4 Mar 19